Triplet Delays Breast Cancer Progression in First-Line Maintenance Setting

By News Health
1 hour Ago

(MedPage Today) — SAN ANTONIO — Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab and pertuzumab (Perjeta) significantly improved progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118958

Author :

Publish date : 2025-12-11 17:19:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

RFK Jr. Tops This Year's Shkreli Awards

Should Congress Intervene in the Newborn Hep B Vaccine Controversy?

Wes Streeting confirms public inquiry into Teesside NHS trust

Hospitals hit by 'super flu' wave with no sign when peak will come

Flipped-Dose Immunotherapy May Improve Melanoma Outcomes

Gender Care Docs Accused of Fraud; Army Ob/Gyn Criminally Charged; Nurse Sentenced